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Abstract
Background: A kinetic model analysis was recently proposed to estimate the 18F-fluorodeoxyglucose (18F-FDG)
integrated activity in an arbitrary tissue that uses tracer uptake and release rate constants. The aim of the current
theoretical paper was to estimate 18F-FDG integrated activity using one standardized uptake value (SUV).
Methods: A further kinetic model analysis allowed us to derive an analytical solution for integrated activity
determination, involving both irreversible and reversible trapping. It only uses SUV, which is uncorrected for
18F physical decay (SUVuncorr, in g.mL
−1) and is assessed about its peak value. Measurement uncertainty of the
estimate was also assessed.
Results: In a tissue (volume V, in mL) that irreversibly traps 18F-FDG, the total number of disintegrations can be
estimated as: ÃC = 162 * 10
5 * SUVuncorr * V * ID / W (ID, injected dose, in MBq; W, patient’s weight, in kg), where
SUVuncorr is a mean over V and is assessed between 55 and 110 min after tracer injection. The relative uncertainty
ranges between 18% and 30% (the higher the uptake, the lower the uncertainty). Comparison with the previous
Zanotti-Fregonara’s model applied to foetus showed less than 16% difference. Furthermore, calculated integrated
activity estimates were found in good agreement with Mejia’s results for healthy brain, lung and liver that show
various degrees of tracer trapping reversibility and various fractions of free tracer in blood and interstitial volume.
Conclusion: Estimation of integrated activity in an arbitrary tissue using one SUV value is possible, with
measurement uncertainty related to required assumptions. A formula allows quick estimation that does not
underestimate integrated activity so that it could be helpful in circumstances such as accidental exposure, or for
epidemiologic purposes such as in patients having undergone several examinations.
Keywords: 18F-FDG dosimetry, Integrated activity, Kinetic modelling, SUV
Background
18F-fluorodeoxyglucose positron emission tomography
(18F-FDG PET) imaging has become indispensible for
managing many diseases, either malignant or benign
[1,2]. However, in all nuclear medicine procedures, it is
important to assess the absorbed dose deposited from
internally distributed radionuclides. This assessment re-
quires combination of integrated activity in source re-
gions and of the so-called S values that relate mean
absorbed dose in an arbitrary region to integrated activ-
ity in source regions [3,4]. Since the level of irradiation
induced by diagnostic examinations remains well below
the threshold of appearance of deterministic effects, a
degree of simplification can be accepted for absorbed
dose determination. Tables of S values derived from an-
thropomorphic mathematical phantoms are given in
MIRD pamphlets for various radionuclides and organs.
Average integrated activity, i.e. the total number of disin-
tegrations that occur from the time of tracer administra-
tion (zero) to (theoretically) infinity, or the mean
residence time (ratio of integrated activity to injected ac-
tivity), can be derived from healthy volunteer studies, or
from a number of examinations in patients [5]. ‘Model-
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based’ dosimetric approaches are usually considered as
sufficient to deduce a first order estimate of irradiation
induced by the nuclear medicine procedure [6]. How-
ever, even in current clinical 18F-FDG PET imaging, get-
ting a better estimate (i.e. more patient-specific) of the
absorbed dose may be relevant, although the only avail-
able parameter for 18F-FDG uptake is semi-quantitative,
i.e. the standardized uptake value (SUV) index. As an ex-
ample, a first estimation has been made a posteriori by
Zanotti-Fregonara et al. (Z-F) for an 18F-FDG examin-
ation accidentally performed during pregnancy [7,8]. It
could also be helpful for epidemiologic purpose such as
in patients having undergone numerous examinations.
A kinetic model analysis was recently proposed to cal-
culate the integrated activity in an arbitrary tissue for
18F-FDG PET imaging, and its efficacy was demon-
strated in the brain [9]. That study used 18F-FDG uptake
and release rate constants for grey matter and white
matter, which were calculated from literature data in-
volving dynamic acquisitions, i.e. involving several mea-
surements [10]. In comparison, the aim of the present
theoretical work was to investigate whether an estimate
of 18F-FDG integrated activity in an arbitrary tissue can
be computed by only using SUV obtained from a single
static acquisition. For this, an analytical solution derived
from a kinetic model analysis was established, involving
a population-based input function. This analytical solu-
tion allows determination of integrated activity that only
uses SUV uncorrected for 18F physical decay (SUVuncorr)
and assessed about its peak. A formula was derived that
was compared to that of Z-F and its results for foetus,
assuming irreversible trapping [7,8]. Furthermore, esti-
mates for healthy brain, lung and liver that show various
degrees of tracer trapping reversibility and various frac-
tions of free tracer in blood and interstitial volume, were
calculated from this analytical solution and literature
data, and were compared to results published by Mejia
et al. [11]. This work also assesses the measurement un-
certainty of the integrated activity estimation that is re-
lated to required assumptions.
Methods
Kinetic model analysis
Let us define the SUV at time t, normalized to body
weight, and corrected for 18F physical decay, i.e.
SUVcorr(t) (g.mL
−1) [12]:
SUVcorr tð Þ ¼ ATot tð ÞW=ID ð1Þ
where ATot(t) is the whole
18F-FDG activity per tissue
unit volume at time t (kBq.mL−1), which is corrected for
18F physical decay (and includes trapped tracer and free
tracer), W is the patient’s weight (kg), and ID is the
injected dose (MBq).
First, the dosimetry purpose of this work requires cal-
culation of the area under the curve (AUC) of the tissue
activity changes with time, i.e. the AUC of the so-called
tissue time activity curve (TAC). For this, the results of a
previous study are summarized below [9]. A two-
compartment model analysis was previously developed
to assess radiotracer uptake in tissues, assuming con-
stant uptake and release rates, K (min−1) and kR (min
-1),
respectively (in comparison with the three-compartment
model of Sokoloff et al. [13], K is (k1k3) / (k2 + k3) and
kR is (k2k4) / (k2 + k3)). The rate of trapped radiotracer
change per tissue unit volume at steady state, i.e.
dCTrap / dt (mL
−1 min−1), is described by the following
differential equation:
dCTrap tð Þ=dt ¼ KCp tð Þ  kRCTrap tð Þ  λCTrap tð Þ ð2Þ
where Cp(t) is the number of tracer molecules per
plasma unit volume at time t (mL−1), and λ is the 18F
physical decay constant (min−1). Equation 2 yields the
TAC of trapped 18F-FDG per tissue unit volume at time
t, i.e. ATrap(t):
ATrap tð Þ ¼ λCTrap tð Þ
¼ K
X3
i¼1
λCi e
 λþkRð Þt  eαit
 
= αi  λ kRð Þ
ð3Þ
where Ci and αi are the coefficients of the
18F-FDG input
function (IF), which is usually assumed to be a three-
exponential curve [14,15]. Such a shape for the IF allows
a simple analytic integration of ATrap(t) from zero to in-
finity, providing integrated activity for trapped 18F-FDG
per tissue unit volume (mL−1). Furthermore, adding the
part of free 18F-FDG in blood and reversible compartment,
i.e. F (no unit), and hence extending the initial two-
compartment model to a three-compartment model, pro-
vides total integrated (cumulated) activity for 18F-FDG, i.e.
the total number of disintegrations ÃC (no unit) occurring
in a tissue volume (V/mL) [9]:
eAC ¼ V F þ K= λþ kRð Þ½ X
3
i¼1
λCi=αið Þ ð4Þ
where ‘Σ(λCi/αi)’ is the input function AUC of the tracer
(AUCIF; in mL
−1).
Second, because in the present framework the only
available parameter for 18F-FDG uptake is the SUV, it is
then necessary to focus on the ratio K / (λ + kR) (i.e. up-
take / (decay + release)) in the right hand side of
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Equation 4 and to find a further relationship between
the parameters. Therefore, let us consider the following
equation that temporarily put aside F:
eAC≅ V K= λþ kRð Þ½  AUCIF ð5Þ
and let us write that at the trapped tracer peak, i.e. when
dCTrap / dt = 0, Equation 2 yields:
K Cp tpeak
 
¼ λþ kRð Þ CTrap tpeak
 
ð6Þ
As a result, the combination of Equations 1, 5 and 6
provides the following expression for 18F-FDG integrated
activity in a tissue:
eAC≅ SUVuncorr tpeak   V  ID=W½ 
AUCIF=λCp tpeak
  
ð7Þ
where SUVuncorr(t) is SUV that is not corrected for
18F
physical decay. It should be noted that the use of
SUVuncorr(tpeak) in Equation 7, i.e. the use of ATot(tpeak)
instead of ATrap(tpeak), involves the activity of both
trapped and free tracer in blood and reversible compart-
ment, the latter being related to F that was temporarily
put aside in Equation 5.
Third, deriving a formula from Equation 7 requires
that the second ratio appearing in the right-hand-side of
Equation 7 be calculated. In this connection, this ratio
can be expressed by means of a normalized input func-
tion for injected dose and initial distribution volume, i.e.
[AUCNIF / λCpN(t)], as proposed by Vriens et al. from a
patient population [15]. Thus,
eAC≅ SUVuncorr tpeak  V ID=W 
AUCNIF=λCpN tpeak
  
ð8Þ
Alternatively, Equation 8 can be expressed by using
Equation 1 as
eAC≅ ATot:uncorr tpeak   V  AUCNIF=λCpN tpeak  
ð9Þ
where ATot.uncorr(tpeak) is the peak radioactive concentration
(kBq.mL−1), which is not corrected for 18F physical decay.
Z-F model
Zanotti-Fregonara et al. assessed 18F-FDG integrated ac-
tivity in embryo assuming (a) instantaneous tracer up-
take, (b) irreversible trapping and (c) the maximal SUV
(hottest pixel; corrected for 18F physical decay) recorded
60 min after the injection, could be taken as an initial
activity concentration that exponentially decays with
time [7,8]. In other words, the total number of disinte-
grations ÃZ (no unit) occurring in embryo volume V
(mL), was obtained from the area under the curve
(AUC) of the function ‘ATot(t = 60) * exp(−λt)’, which is
eAZ≅ VATot 60ð Þ=λ ¼ SUVcorr 60ð Þ VID=λW½ 
ð10Þ
Assuming irreversible trapping in our model, compari-
son with Z-F model, i.e. comparison of Equations 8 and
10, is equivalent to comparing two ratios, i.e. [AUCNIF /
λCpN(tpeak)] versus [exp(60λ) / λ], respectively.
Note that the two models lead to a very close final
equation when it is assumed that (a) tracer is trapped ir-
reversibly and (b) tracer plasma decay is tracer physical
decay, as shown in the Appendix.
Results
Curve a in Figure 1 was obtained from Equation 3 for ir-
reversible trapping, showing that tissue activity peaks at
t = 79 min (leading to a [AUCNIF / λCpN(tpeak)] ratio of
269 min), by using median values for the time constants
of the normalized 18F-FDG input function of Vriens
et al. [15] [in comparison with Vriens et al. results (Table
two-first column) the decay constants were modified in
our model to take 18F physical decay into account].
Using minimal and maximal inter quartile values for
these time constants leads to a [AUCNIF/λCpN(tpeak)] ra-
tio of 272 and 262 min, for tissue activity peak at 82 and
76 min, respectively. In other words, the relative differ-
ence between the ratio obtained and minimal and max-
imal inter-quartile values is 3.8%. An estimate of
integrated activity occurring in a tissue volume (V, in
mL) can be computed from either Equation 8 or 9, and
using AUCNIF / λCpN(tpeak) = 269 min, as
eAC≅ 162 105  SUVuncorr tpeak  V  ID=W ð11Þ
eAC≅ 162  105  ATot:uncorr tpeak  V ð12Þ
Curve a in Figure 1 also shows that when SUVuncorr
in Equation 11 (or peak radioactive concentration
ATot.uncorr in Equation 12) is assessed at t = 55 min or
t = 110 min after injection, it is 5% lower than that
obtained at peak time t = 79 min.
Furthermore, Figure 1 compares the plots of the
18F-FDG TAC from Equation 3 (curve a) and of the
function ATot(t = 60) * exp(−λt) from Z-F model (curve
b). Curve b was plotted using the value of ATot(t = 60)
obtained in curve a. The area under each curve is the in-
tegrated activity assessed from each model, respectively.
Figure 1 visually suggests that the two AUCs are very
close. This visual interpretation is confirmed by the
comparison between the ratios [AUCNIF / λCpN(tpeak)]
and [exp(60λ) / λ], which only differ by 16%: 269 min
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versus 232 min, respectively. In this connection, the total
number of disintegrations occurring in the foetus
obtained from the present study and from the Z-F model
[8] (SUVcorr(t = 60) = 4.5 g.mL
-1, V = 21 mL, and 71-kg
mother) is estimated to 14,720,000 and 12,623,000/MBq
injected to the mother, respectively. Comparison be-
tween the [AUCNIF / λCpN(tpeak)] and [exp(60λ) / λ] ra-
tios further indicates that the two AUCs in Figure 1
would be equal if the SUV was acquired at t = 84 min
after injection (curve c) (alternatively, the two AUCs can
also be equal when a low 18F-FDG release occurs in the
tissue of interest, resulting in a lower AUC of the tissue
TAC and in a shift of peak time to t = 77 min, instead of
t = 79 min).
For healthy grey and white matter, which reversibly trap
18F-FDG, the [AUCNIF / λCpN(t)] ratio is 185 and 189 min,
for peak activity at t = 61 and 63 min [9,10], respectively.
For the healthy brain, integrated activity was calculated
from Equation 8, assuming that brain was 50% gray and
50% white matter, with 805-mL volume each (as 2.3% of a
70-kg patient, with a brain density of 1) [10,16]. For
SUVuncorr(tpeak = 60) = 4 g.mL
−1 (= (5.3 + 2.7) / 2, on aver-
age [17]) and ID = 37 MBq, the total integrated activity for
healthy brain compares with that calculated by Mejia
et al.: 7.97 versus 6.57 (±1.51) MBq.h [11].
For the healthy lung, which irreversibly traps
18F-FDG, integrated activity was calculated from
Equation 12 and experimental literature data [18].
Assuming that lung volume is 1,120 mL (as 1.6% of
a 70-kg patient, with lung parenchyma density of 1) [16],
for ATot.uncorr(tpeak) = 1.62 kBq.mL
−1 on average (Table one
in [18]), the total integrated activity for healthy lung com-
pares with that calculated by Mejia: 0.93 versus 0.86 (±0.10)
MBq.h for an administered activity (ID) of 37 MBq [11].
For the healthy liver, which reversibly traps 18F-FDG,
the [AUCNIF / λCpN(t)] ratio is 164 min, for peak activity
at about t = 55 min (Figure two in [19]). Total peak ac-
tivity is 8.6 kBq/mL, and hence SUVuncorr(tpeak) = 1.7
g.mL-1, a value identical to that obtained by Minamimoto
et al. [17]. The total integrated activity was calculated
from Equation 12, assuming that liver volume is 1,280
mL (as 2.0% of a 64-kg patient, with liver parenchyma
density of 1) [16]. The total integrated activity for healthy
liver compares with that calculated by Mejia: 3.47 versus
4.14 (±1.09) MBq.h, for an administered activity (ID) of
37 MBq [11].
Discussion
Analytical solution of integrated activity
This theoretical work showed that the calculation of an es-
timate of integrated activity in an arbitrary tissue using
one SUV value, or using one radioactive concentration
value (Equation 8 and 9, respectively), is possible. How-
ever, this estimation requires the following: (a) the use of a
population-based input function [15], which is involved in
the [AUCNIF / λCpN(tpeak)] ratio (Equations 8 and 9) and
(b) the use of SUV, which is uncorrected for 18F physical
decay (either to the time of injection or to the beginning
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Figure 1 Model comparison. Curve (a) Trapped tracer activity (in arbitrary unit) versus time (in minutes) from Equation 3, assuming irreversible trapping,
and the input function of Vriens et al. for 18F-FDG was used [15]. Curve (b) (full line) Z-F function, i.e. ATot(t = 60) * exp(−λt) (the value for ATot(t=60) was
taken from curve a). Curve (c) (dotted line) Z-F function with ATot(t = 84) (instead of ATot(t = 60)) that gives similar AUC for the two models.
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of acquisition) and is assessed about its peak value. The
value of 18F-FDG release rate constant in the tissue of
interest plays a role in the peak timing and hence in the
value of CpN(tpeak) (indeed, Equation 3 shows that the peak
timing depends on the release rate constant, on the phys-
ical decay constant, and on the time constants of the
18F-FDG IF, whereas the uptake rate constant plays a role
in the SUVuncorr(tpeak) amplitude). If the
18F-FDG release
rate constant from the tissue is unknown, and hence if the
SUVuncorr peak time is unknown, assuming that kR is neg-
ligible (i.e. an irreversible trapping) leads to an overesti-
mate. In current clinical practice, this overestimate is
more acceptable than an underestimate and can be very
quickly computed as ÃC = 162 * 10
5 * SUVuncorr(tpeak) * V
* ID/W (Equation 11).
The use of the semi-quantitative SUV index obtained
from a single acquisition for integrated activity estima-
tion requires assumptions presented above, resulting in
different origins of measurement uncertainty. The meas-
urement uncertainty that is related to the product ‘162 *
105’, i.e. related to the [AUCNIF / λCpN(tpeak)] ratio, was
estimated to be ±3.8%, i.e. the relative difference be-
tween the [AUCNIF / λCpN(tpeak)] ratio obtained by using
minimal and maximal inter quartile values for the time
constants of the normalized 18F-FDG IF of Vriens et al.
[15]. Although this relative uncertainty is low, it is sug-
gested that it could be still reduced by using, in each pa-
tient, a more specific IF adjusted with a single blood
sample, instead of a population-based input function, as
proposed by authors [14,20]: in other words, Equation 7
could be used instead of Equation 8. Note that such a
method could be applied in particular in hyperglycaemic
patients, while SUVuncorr(tpeak) (even if it is lowered owing
to a high blood glucose level) should be used as such, with
appropriate measurement uncertainty discussed below.
First, in current clinical practice, a strict time delay be-
tween injection and acquisition cannot be always fulfilled
to obtain SUVuncorr peak value. However, curve a in
Figure 1 shows that trapped tracer radioactive concentra-
tion, and hence SUVuncorr, smoothly peaks at t = 79 min,
and at t = 55 min or t = 110 min after injection, i.e. a typ-
ical acquisition time window, its value is 5% lower than
that obtained at peak time. Second, SUV in itself involves
a relative measurement uncertainty, which is the same for
SUV either corrected or uncorrected for physical decay. In
a recent study, de Langen et al. [21] showed that SUVmax
repeatability, and hence SUVmax measurement uncer-
tainty, was significantly greater than that of SUVmean, i.e.
SUV averaged over several voxels. Therefore, the use of
SUVmean appears relevant for dosimetry purpose. It can
be obtained over a tissue volume, exhibiting either homo-
geneous or heterogeneous 18F-FDG uptake, as well as over
a volume of interest within heterogeneous uptake (in this
connection, the brain that is built of white and grey matter
may be considered as an example of heterogeneous up-
take). The SUVmean measurement uncertainty can be es-
timated from Figure two C in De Langen et al. study
showing a minimal-maximal repeatability of 13% to 30%
(with 95% confidence limit), leading then to a relative
measurement uncertainty of 9.2% to 21.2% (=13/21/2 to
30/21/2). However, it should be noted that the use of the
SUVmax value over a tissue volume, instead of SUVmean,
may provide an overestimate (that is more acceptable than
an underestimate), and the SUVmax measurement uncer-
tainty can be obtained in the study of de Langen [21].
As a summary, for estimation of integrated activity
from Equation 11: SUVuncorr may be averaged over the
tissue volume and should be assessed between 55 and
110 min after injection. The total uncertainty of the esti-
mate ranges between 18% and 30% (as 18 = 3.8 + 5 +
9.2 and 30 = 3.8 + 5 + 21.2, i.e. simply summing the
measurement uncertainties of different origins, respect-
ively), depending on the tissue uptake: the higher the
uptake, the lower the uncertainty.
Comparison with Z-F model
To the very best of our knowledge, the only previously
published analytical solution for estimating integrated
activity from one SUV value was that of Zanotti-
Fregonara et al. in the framework of foetal dosimetry.
This is the reason why the present model was compared to
that of Z-F [7,8]. The results of the two models, assuming
irreversible trapping, were found in very good agreement
with only a 16% difference. It is suggested that this differ-
ence is very likely overestimated. Indeed, the model com-
parison indicates that the estimates would be equal if the
SUV was acquired at t = 84 min after injection (comparison
of the AUC of curve a to curve c in Figure 1). A 16% differ-
ence was found with SUV obtained at 60 min after tracer
injection, but this time delay is that of the start of the whole
imaging procedure and not that of the particular step of
PET imaging that involved the tissue of interest (embryo).
Zanotti-Fregonara et al. indicated that imaging was
obtained from the base of the skull to the mid-thigh level
(7 table positions, 3-min per position). If so, taking also into
account the time duration of the CT, the actual time delay
between injection and acquisition was very likely longer
than 60 min, and hence closer to 84 min. As a summary, it
is suggested that the agreement between the two models
mainly comes from (a) the common assumption that SUV
is assessed about the SUVuncorr peak and (b) that the
18F
half-life somewhat dominates the decay of the trapped 18F-
FDG TAC, as visually shown by Figure 1. Nevertheless, it is
suggested that the main benefit of the proposed model over
the Z-F model is that reversible trapping is also addressed.
Furthermore, in the framework of foetal dosimetry, it
should be noted that both models can only provide a
rough estimate of the integrated activity, because several
Laffon et al. EJNMMI Research 2013, 3:26 Page 5 of 7
http://www.ejnmmires.com/content/3/1/26
unknown factors may influence the 18F-FDG uptake by
the foetal tissues. In particular, foetal blood glucose level
depends on that of the mother because glucose mole-
cules can pass through the placental barrier, and there-
fore it is reasonable to assume a similar fate for glucose
analogue molecules like 18F-FDG molecules. However, a
main limitation of the integrated activity estimation from
the two models is that the foetal 18F-FDG IF may be dif-
ferent from that of the mother. In addition, it should be
noted that the foetal dosimetry should also involve the
bladder as a source region, because it is close to the
foetus and it is filled with urinary 18F-FDG [22].
Comparison with Mejia’s results
Calculated integrated activity estimates were found in
good agreement with Mejia’s results for healthy brain, lung
and liver that show various degrees of tracer trapping re-
versibility and various fractions of free tracer in blood and
interstitial volume. Healthy brain reversibly traps 18F-FDG
and F is much lower than the ratio K / (λ + kR): 4.6% and
5.9% for grey and white matter, respectively [9]. Healthy
lung irreversibly traps 18F-FDG and F is not negligible in
comparison with the ratio K / (λ + kR): 63% at peak time
[18]. Healthy liver reversibly traps 18F-FDG and F is not
negligible in comparison with the ratio K / (λ + kR): 26%
at peak time [19]. Furthermore, it should be noted that
neglecting reversibility of the 18F-FDG uptake in healthy
brain and liver leads to an overestimation of integrated ac-
tivity that can be approached by comparing the [AUCNIF /
λCpN(tpeak)] ratio obtained at t = 62 and 55 min to that
obtained at t = 79 min (=269/187 and 269/164), which dif-
fers by 44% and 64%, respectively: the greater the release
rate constant, the greater the overestimation.
Furthermore, Mejia et al. assume a two-exponential decay
for lung and liver TAC and a five-exponential decay for brain
TAC that can be applied to experimental tissue data, respect-
ively [11]. In comparison, the present study assumes a multi-
exponential decay of the tracer IF leading to an analytical ex-
pression for integrated activity (Equation 4) that involves the
sum ‘Σ(λCi/αi)’, which is the AUC of the tracer IF. This sum
is close to the sum expressed in the right hand side of
Equation A4 obtained by Mejia [11], thus suggesting that for
integrated activity estimation, assuming a multi-exponential
decay of the tissue TAC should be implicitly connected to
assuming a multi-exponential decay of the tracer IF.
Conclusions
This theoretical work showed that an estimate of cumu-
lated activity in an arbitrary tissue can be computed from
an equation that involves the tissue SUV, which is used
without physical decay correction and is assessed about its
peak (i.e. SUVuncorr(tpeak)). Furthermore, if the
18F-FDG re-
lease rate constant from the tissue is unknown, in other
words, if peak time of SUVuncorr is unknown, this work
shows that assuming an irreversible trapping leads to an
overestimate. This overestimate is more acceptable than an
underestimate and can be very quickly computed as ÃC =
162.105 * SUVuncorr * V * ID/W (V, tissue volume, in mL;
ID, injected dose, in MBq; W, patient’s weight, in kg),
where SUVuncorr is a mean over V and is assessed between
55 and 110 min after injection. However, this calculation
requires assumptions leading to a relative measurement
uncertainty for the estimate that ranges between 18% and
30% (the higher the uptake, the lower the uncertainty). It is
suggested that estimating 18F-FDG integrated activity using
one SUV value could be helpful in circumstances such as
accidental exposure, or for epidemiologic purposes such as
in patients having undergone several examinations.
Appendix
When the present model is developed assuming that (a)
tracer is trapped irreversibly, i.e. kR = 0, and that (b)
tracer plasma decay equals the tracer physical decay,
Equation 5 becomes:
eAK≅ V K Cp t ¼ 0ð Þ =λ ð13Þ
where Cp(t = 0) is the number of tracer molecules per
plasma unit volume (in mL−1) at the time of injection.
Furthermore, when kR = 0, at the trapped tracer peak
Equation 6 becomes:
K Cp tpeak
 
¼ λ CTrap tpeak
 
ð14Þ
When tracer plasma decay equals tracer physical
decay, i.e. Cp(tpeak) = Cp(t = 0) * exp(−λtpeak), combining
Equations 1, 13 and 14 provides a further expression for
18F-FDG integrated activity in a tissue as follows:
eAK≅ SUVcorr tpeak   V  ID=λW½  ð15Þ
where SUVcorr(tpeak) is SUV that is corrected for
18F physical
decay and that is assessed at the trapped tracer peak, which
is t = 160 min, as shown in a previously published work
[23]. Comparison of Equations 10 and 15 shows they are
very close except that SUVcorr is not assessed at the same
time delay after injection, i.e. 60 and 160 min, respectively.
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